mRNA as novel technology for passive immunotherapy
نویسندگان
چکیده
منابع مشابه
Active and passive immunotherapy for neurodegenerative disorders.
Immunotherapeutic strategies to combat neurodegenerative disorders have galvanized the scientific community since the first dramatic successes in mouse models recreating aspects of Alzheimer disease (AD) were reported. However, initial human trials of active amyloid-beta (Abeta) vaccination were halted early because of a serious safety issue: meningoencephalitis in 6% of subjects. Nonetheless, ...
متن کاملA Novel Passive Method for Islanding Detection in Microgrids
Integration of distributed generations (DGs) in power grids is expected to play an essential role in the infrastructure and market of electrical power systems. Microgrids are small energy systems, capable of balancing captive supply and requesting resources to retain stable service within a specific boundary. Microgrids can operate in grid-connected or islanding modes. Effective islanding detec...
متن کاملIdentification of novel immune checkpoints as targets for cancer immunotherapy
Members of the B7/CD28 family of immune checkpoints, such as CTLA4, PD1 and PDL-1, play critical roles in T cell regulation, and have emerged as promising drug targets for cancer immunotherapy. We hypothesize that additional novel members of the B7/CD28 family play a role as negative immune regulators, and thus may serve as targets for therapeutic mAbs. Utilizing Compugen’s predictive discovery...
متن کاملAutologous Immunotherapy as a Novel Treatment for Bladder Cancer
Cancer is fundamentally a disease with failure in regulation in tissue growth and the risk of developing cancer increases with age. The armamentarium in treating cancer is mainly threefold: surgical resection of the tumor, radiation therapy and cytotoxic drugs. For blad‐ der cancer, results from contemporary radical cystectomy series with pelvic lymph node dis‐ section for T2-4 NX M0 transition...
متن کاملDKK1 as a novel target for myeloma immunotherapy
Novel, potent tumor-associated antigens are needed to improve the efficacy of immunotherapy for myeloma. We demonstrated that active vaccination using the DKK1-DNA vaccine in the myeloma mouse model protected mice from developing myeloma and effectively treated established myeloma. Therefore, DKK1 could be developed as a novel vaccine for myeloma immunotherapy.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cellular and Molecular Life Sciences
سال: 2018
ISSN: 1420-682X,1420-9071
DOI: 10.1007/s00018-018-2935-4